A Phase 2/3 interventional study of Sensorcaine with Epinephrine and Sham injection in Sinus Disease, Anesthesia and Bleeding, sponsored by Amin Javer. Recruiting at 1 site in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-05-15.
Sponsored by Amin Javer · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Endoscopic sinus surgery (ESS) is a common otolaryngologic procedure that aims to remove the partitions that separate the sinus cavities, remove inflamed tissue, and optimize the sinuses for topical medication use. In this procedure, the surgeon will inject a combination of drugs, local anesthetics, and vasoconstrictors, to reduce bleeding and improve visualization. However, previous studies have shown similar results when injected with only saline. In this study, investigators want to determine if the injection of local anesthesic+vasoconstrictor compared to no injection at all makes any difference in improving the surgeon's visualization during an ESS.
24 studies on the registry are indexed under Paranasal Sinus Diseases; 7 are open to participants now.
This study's planned enrollment of 80 is close to the median of 80 across 16 interventional studies indexed under Paranasal Sinus Diseases.
Browse Paranasal Sinus Diseases studies →Amin Javer is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
- Injection 0.25% bupivacaine with 1:200,000 epinephrine
Drug: Sensorcaine with Epinephrine
- Sham injection (only puncture, no injecting anything)
Other: Sham injection
Drug pages: BupivacaineStudies of BupivacaineBupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · EpinephrineStudies of EpinephrineEpinephrine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
The combination contains 0.25% bupivacaine hydrochloride (2.5 mg/mL) and epinephrine bitartrate \[(1:200,000) 5 mcg/mL\] per vial.
Punctures without any medication injected onto the septum
Boezzart bleeding score
Change in mean surgical field quality as determined by the Boezzart bleeding score. Boezaart score of 0 indicates no bleeding, whereas the maximum score of 5 indicates severe bleeding (constant suctioning required).
Time frame: throughout study completion, one day study visit
Total blood loss
Change in total blood between injection and sham group measured in millilitres
Time frame: throughout study completion, one day study visit
Surgical time
Change in surgical time between injection and sham group measure in minutes
Time frame: throughout study completion, one day study visit
Mean arterial pressure (MAP)
Change in Mean arterial pressure (MAP) between injection and sham group measured in millimeters of mercury (mm Hg)
Time frame: throughout study completion, one day study visit
Postoperative bleeding
Change in postoperative bleeding between injection and sham group measured in mililiters
Time frame: throughout study completion, one day study visit
Postoperative pain
Change in postoperative pain between injection and sham group measured with a Visual Analog Scale (VAS) grading from 0 (no pain) to 5 (severe pain)
Time frame: throughout study completion, one day study visit
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for May 2025, 6 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bupivacaine · Epinephrine
Amin Javer